GDF15 (growth differentiation factor 15) is a part of the transforming growth factor-ß (TGFß) or bone morphogenetic protein (BMP) superfamily. This gene resides in human chromosomal locus 19p12.1-13.1, and contains two exons. The pro-protein is a dimer containing a disulfide linkage which undergoes cleavage at RXXR sequence, by furin-like protease. The mature protein is a C-terminal dimer composed of 112 amino acids.
Synonyms: Anti-Growth/differentiation factor 15 precursor; Anti-MIC-1; Anti-Macrophage inhibitory cytokine 1; Anti-NAG-1; Anti-NRG-1; Anti-NSAID-regulated protein 1; Anti-Placental TGF-beta; Anti-Placental bone morphogenetic protein; Anti-Prostate differentiation factor
Storage: -20C
Application: Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.Immunoprecipitation (1 paper)Western Blotting (1 paper)
Biochem Physiol Actions: GDF15 (growth differentiation factor 15) is released in response to stress such as, inflammation, oxidative stress and hypoxia, from multiple tissues, such as heart and liver. Studies show that it is responsible for the down-regulation of microRNAs of muscles, leading to intensive care unit-acquired weakness (ICUAW) and related muscle atrophy. It also controls the developmental processes underlying embryogenesis, osteogenesis, and hematopoiesis. It also regulates adipose tissue function, cartilage and bone synthesis and immune response. It is involved in tissue injury and repair processes. It is up-regulated in melanoma, thyroid, breast, pancreatic, gastrointestinal, prostate and colorectal cancer. It is involved in tumorigenesis, and abnormal expression is related to poor prognosis in various cancers. It is a biomarker for multiple epithelial cancers such as, renal cell carcinoma, adenocarcinoma of the esophagus, ovary and colon. In glioblastomas, it acts as a tumor suppressor gene and induces apoptosis.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC